Viewing Protocol Section

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT04872634
Ignite Creation Date: 2024-05-06 @ 4:07 PM
Last Modification Date: 2024-10-26 @ 2:03 PM
Study NCT ID: NCT04872634
Protocol Section: NCT04872634
Start Identification Module Data
Expand Identification Module Data
Brief Title: A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 NK Cells Administered in Combination With Chemotherapy or Chemotherapy Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment
Official Title: A Phase IIIa Open Single-Center Clinical Trial Evaluating the Safety and Anti-Tumor Activity of SNK01 Natural Killer Cells Administered in Combination With GemcitabineCarboplatin or GemcitabineCarboplatinCetuximab to Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Have Failed Prior Tyrosine Kinase Inhibitor TKI Therapy SNK_ASTER
Acronym: SNK_ASTER
Organization: NKMAX Co Ltd
Organization Class: INDUSTRY
Organization Study ID: SNK01_TRN12a
Start Status Module Data
Status Verified Date: 2021-07
Overall Status: UNKNOWN
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: NKMAX Co Ltd
Lead Sponsor Class: INDUSTRY
Lead Sponsor: NKMAX Co Ltd
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload